Theravance Biopharma
TBPH
TBPH
119 hedge funds and large institutions have $696M invested in Theravance Biopharma in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 39 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
0% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 39
2% less funds holding
Funds holding: 122 → 119 (-3)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
Holders
119
Holding in Top 10
5
Calls
$13.2M
Puts
$1.63M
Top Buyers
| 1 | +$3.5M | |
| 2 | +$3.48M | |
| 3 | +$2.5M | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.29M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$1.37M |
Top Sellers
| 1 | -$22.4M | |
| 2 | -$11.7M | |
| 3 | -$5.02M | |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$3.61M |
| 5 |
C
Chescapmanager
Baltimore,
Maryland
|
-$3.47M |